Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEKASYS: Propranolol or Spironolactone in Liver Cirrhosis
NCT00332904Phase 4Unknown
- Sponsor
- Copenhagen University Hospital - Hvidovre
- Start
- Aug 2006
- Primary completion
- Jul 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of propranolol and spironolactone in Liver cirrhosis (LC) and Portal Hypertension (PH), sponsored by Copenhagen University Hospital - Hvidovre. Primary endpoints: Hemodynamic and cardiac parameters at 3 weeks and Peripheral and cardiac oxygenation at 3 weeks. Status: unknown.
02
Drugs
propranololspironolactone
03
Conditions
Liver cirrhosis (LC)Portal Hypertension (PH)
Beyond the preview
Go deeper on NCT00332904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00332904.